Compare Crispr Therapeutics AG (CRSP) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Crispr Therapeutics AG trades at $50.59 (market cap $4.97B), while iShares 20 Plus Year Treasury Bond ETF trades at $84.3. Which is the better fit depends on your goals.
| CRSP | TLT | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | — |
52-Week High | $76.78 | $92.06 |
52-Week Low | $44.34 | $83.02 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
TLT trades at $83.97, down 0.59% with a bearish technical signal from moving averages. The ETF faces mixed sentiment as fixed income sees renewed interest amid economic uncertainty. Recent dividend payments of $0.32-$0.34 highlight income generation, while technical indicators show oversold conditions with RSI at 27.67 suggesting potential rebound opportunity.
Long-term Treasury bonds offer attractive yields but face interest rate sensitivity. The Fed's hawkish stance presents near-term headwinds, though TLT's 4-5x higher starting yields than pre-crisis levels provide income appeal. Investors must weigh duration risk against potential Fed policy shifts and inflation trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
